Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls

NCT ID: NCT01860963

Last Updated: 2013-10-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

310 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to establish the prevalence of anal squamous intraepithelial lesion (ASIL) in patients with inflammatory bowel disease (IBD) and healthy controls.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

IBD patients attending the Stanford Inflammatory Bowel Disease (IBD) clinic and age-matched healthy controls are screened for eligibility. Informed consent is obtained for eligible subjects. An anonymous self-administered questionnaire is administered to assess risk factors for HPV. For IBD patients, information regarding IBD diagnosis and treatment is obtained.

An anal pap smear is performed at the time of a clinic visit or at the time of an already scheduled colonoscopy. Samples are collected and processed at Stanford pathology where a blinded pathologist reads all specimens. Human Papillomavirus (HPV) DNA testing is performed on all specimens. All patients with anal squamous intraepithelial lesion (ASIL) are referred to a colorectal surgeon for further recommendations or treatment, which includes a high-resolution anoscopy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anal Squamous Intraepithelial Lesion (ASIL) HPV DNA

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

ASIL Anal dysplasia IBD HPV DNA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IBD patients on immunosuppression

Patients on azathioprine/6-mercaptopurine (6MP), prednisone, methotrexate, infliximab, adalimumab, certolizumab, natalizumab, and etanercept are included.

Group Type ACTIVE_COMPARATOR

Anal Pap smear and HPV DNA testing

Intervention Type PROCEDURE

Anal Pap smear is a standard diagnostic test used for early detection of pre-cancerous cells and anal HPV.

IBD patients off immunosuppressants

Patients off immunosuppressants, on 5-aminosalicylic acid (5-ASA) agents, antibiotics, or no treatment for IBD are included.

Group Type ACTIVE_COMPARATOR

Anal Pap smear and HPV DNA testing

Intervention Type PROCEDURE

Anal Pap smear is a standard diagnostic test used for early detection of pre-cancerous cells and anal HPV.

Healthy controls

Age-matched healthy controls enrolled from the hospital, outpatient clinics, and from the general public via flyers and online advertisements.

Group Type ACTIVE_COMPARATOR

Anal Pap smear and HPV DNA testing

Intervention Type PROCEDURE

Anal Pap smear is a standard diagnostic test used for early detection of pre-cancerous cells and anal HPV.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anal Pap smear and HPV DNA testing

Anal Pap smear is a standard diagnostic test used for early detection of pre-cancerous cells and anal HPV.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All IBD patients followed in the IBD clinic and healthy controls who are greater than 18 years old

Exclusion Criteria

* History of HPV vaccination
* Pregnancy
* Other immunosuppressed states (i.e. systemic lupus erythematosus, rheumatoid arthritis, cancer, Human Immunodeficiency Virus (HIV), transplant)
* IBD patients who don't meet immunosuppression/non-immunosuppression criteria
* Inability to obtain informed consent from patient
* Previous diagnosis of ASIL or anal/rectal cancer
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Stanford University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mark Welton, MD

Role: PRINCIPAL_INVESTIGATOR

Stanford Hosptial and Clinics

Shamita Shah, MD

Role: PRINCIPAL_INVESTIGATOR

Stanford Hospital and Clinics

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Stanford Digestive Health Center

Stanford, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Shah SB, Pickham D, Araya H, Kamal A, Pineda CE, Ghole S, Shih L, Kong C, Pai R, Welton M. Prevalence of Anal Dysplasia in Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2015 Nov;13(11):1955-61.e1. doi: 10.1016/j.cgh.2015.05.031. Epub 2015 Jun 2.

Reference Type DERIVED
PMID: 26044314 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MW-16467

Identifier Type: -

Identifier Source: org_study_id